Q&A: Akeso CEO spells out why she thinks its biliary tract cancer data are a big deal

For Akeso CEO Michelle Xia, the intense spotlight on her company and its PD-1xVEGF bispecific ivonescimab still feels new, despite several years in the headlines as one of the industry's most closely watched drug programs. ...